← signals
2026-07-21·ASML·monopoly stability assessment
lowneutral

Prediction market data from Manifold Markets indicates strong consensus that ASML will retain its monopoly in EUV...

Prediction market data from Manifold Markets indicates strong consensus that ASML will retain its monopoly in EUV lithography through at least 2026 (79.9% for 2026, 70.8% for 2027), and that China does not currently possess an ASML EUV machine (84.4% NO).

window 90devidence 11confidence score 91price ASML $1784.87

confidence score

Strong evidence: 1 independent source class support this read.

91
low confidence1 independent source classesmarketpasses publish gate
priced-in check

ASML has not made a large direction-matching 30-90 day move yet.

not priced in
as of 2026-07-167d n/a45d n/a90d +23%yahoo

signal brief

Prediction market data from Manifold Markets indicates strong consensus that ASML will retain its monopoly in EUV lithography through at least 2026 (79.9% for 2026, 70.8% for 2027), and that China does not currently possess an ASML EUV machine (84.4% NO). However, the market sees a 50% chance the US will force ASML to halt exports to China before 2029, and a 43% chance the US will cut off Cymer, a key supplier, before 2030. These geopolitical uncertainties offset the positive monopoly outlook. The probability of ASML revenue increasing every year for the next five years stands at 83.8%, suggesting investors are broadly bullish but aware of risks. The data does not reflect any single concrete event but rather a snapshot of aggregated expectations.

What the sources said:

  • 'Will ASML remain the world’s only producer of EUV machines until the end of 2026?' → YES=79.92% [source]
  • 'Does China have an ASML EUV machine?' → YES=15.65% [source]
  • 'Will the US force ASML to halt exports to China before 2029?' → YES=50.00% [source]
  • 'Will ASML's revenue increase every year for the next 5 years?' → YES=83.77% [source]

source data used

spillover entities

Decision support, not stock advice. This signal is research with cited evidence — not a recommendation to buy, sell, or hold any security.